Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
MEDISYNALL from Antwerpen, company number BE0754950208, closed financial year 2025 with a result of € -23,418 after tax. For that financial year MEDISYNALL recorded a gross margin of € -2,034 and equity of € -191,319. Compared with financial year 2024, the result moved from € -59,308 to € -23,418. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
€ -191,319
▼ € 23,418 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -23,418
▲ 61 % less loss than in 2024
Profit after tax over the fiscal year.
€ 3,903
▲ € 3,736 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -196,319.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,322
▲ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 208,929 | € 176,573 | € 21,321 | € -2,034 | ▼ € 23,355 |
| Profit after taxes | € -46,742 | € -15,210 | € -59,308 | € -23,418 | ▲ € 35,889 |
| Equity | € -93,383 | € -108,593 | € -167,901 | € -191,319 | ▼ € 23,418 |
| Total debts | € 1,525,922 | € 1,614,857 | € 1,658,720 | € 1,582,878 | ▼ 5% |
| Cash | € 3,251 | € 2,122 | € 167 | € 3,903 | ▲ € 3,736 |
| Land & buildings | € 428,651 | € 414,784 | € 400,918 | € 387,051 | ▼ 3% |
| Retained profit | € -98,383 | € -113,593 | € -172,901 | € -196,319 | ▼ € 23,418 |
| Bank debt | € 1,193,215 | € 1,077,476 | € 0 | € 0 | |
| Balance sheet total | € 1,432,539 | € 1,506,265 | € 1,490,819 | € 1,391,559 | ▼ 7% |
| Employees (FTE) | 3.2 | 2.2 | 1.6 | - |
Key figures of MEDISYNALL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDISYNALL?
What happened at MEDISYNALL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 23,418. Source: NBB ↗
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 46,742 loss in 2022 to € 23,418 loss in 2025.
On average € 13,300 of value added per employee in 2024.
A new publication or filing at MEDISYNALL? We notify you, reason included.
Follow MEDISYNALLDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of AMBIXX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MEDISYNALLBehind MEDISYNALL are Marleen Slaets and Laurent Cooreman. The shares are held by AMBIXX (66%). It owns 100% of Idealpharma itself.
Directors
According to the 2025 annual accounts
Marleen Slaets
Director
Also active at: Apotheek De Voogt, APOTHEEK ZWAANTJE, PHARMA UNITED, AMBIXX, E-pharma, Idealpharma, Apotheek Cauwenbergh
Shareholders
66%
Participations
100%
Establishments
Establishment units
Physical locations of this company
Heidestraat 1
2660 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
ONECOM, DK
Domain
Domain
medisynall.com
Registered
2015-12-03
Registrar
One.com A/S
Expires
2026-12-03
Website info
Features
Security
Network
Details
- Company number
- 0754.950.208
- VAT number
- BE 0754.950.208
- Registered office
- Heidestraat 1, 2660 Antwerpen
- Names & denominations
- MEDISYNALL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2020
- Peppol
- Active · Active since 19 Mar 2025
- Contact
- medisynall.com [email protected]
- Activities · NACE
Activiteiten van holdings
Holdings